{
"id":"mk19_a_on_q051",
"number":51,
"bookId":"on",
"correctAnswer":"C",
"title":"Question 51",
"stimulus":[
{
"type":"p",
"hlId":"5784b0",
"children":[
"A 56-year-old man is evaluated for increasing pain in the mid chest when swallowing. He has not experienced weight loss. Medical history is significant for longstanding gastroesophageal reflux disease. His only medication is over-the-counter famotidine."
]
},
{
"type":"p",
"hlId":"cd8db4",
"children":[
"On physical examination, vital signs are normal. A 3-cm, left supraclavicular lymph node is palpable. The liver edge is palpable 5 cm below the right costal margin."
]
},
{
"type":"p",
"hlId":"28f22d",
"children":[
"Contrast-enhanced CT scan demonstrates a thickening at the gastroesophageal junction and numerous hepatic metastases. The enlarged left supraclavicular node is also noted. An upper endoscopy reveals a mass just above the gastroesophageal junction, and biopsy shows adenocarcinoma."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"983777",
"children":[
"Which of the following is the most appropriate test to perform next?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Assess tumor for <i>BRAF</i> expression"
}
},
{
"letter":"B",
"text":{
"__html":"Assess tumor for epidermal growth factor receptor expression"
}
},
{
"letter":"C",
"text":{
"__html":"Assess tumor for human epidermal growth factor 2 amplification"
}
},
{
"letter":"D",
"text":{
"__html":"PET/CT"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"2663fc",
"children":[
"Gastroesophageal tumors should be evaluated for human epidermal growth factor 2 overexpression."
]
},
{
"type":"keypoint",
"hlId":"bfd989",
"children":[
"Adding trastuzumab to chemotherapy regimens for patients with metastatic gastroesophageal tumors and human epidermal growth factor 2 overexpression provides a modest survival benefit."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"a208b8",
"children":[
"The most appropriate test to perform next is assessment of the tumor for human epidermal growth factor 2 (",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"HER2"
]
},
") amplification (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"). This patient has an adenocarcinoma of the distal esophagus/gastroesophageal junction, which has metastasized to the liver and supraclavicular lymph node. Risk factors for adenocarcinoma include smoking along with gastroesophageal reflux disease (GERD) and obesity. The development of Barrett esophagus as a result of GERD, especially with dysplastic features, is a further risk for developing adenocarcinoma of the esophagus. Pain or difficulty on swallowing, weight loss, nausea, vomiting, or persistent dyspepsia may be presenting symptoms. Upper endoscopy and biopsy establishes the diagnosis. Approximately 25% of such patients will have tumors that show ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"HER2"
]
},
" amplification; such tumors achieve a superior response to chemotherapy when the anti-",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"HER2"
]
},
" monoclonal antibody trastuzumab is added to standard chemotherapy. For this reason, determination of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"HER2"
]
},
" amplification status is necessary when initiating chemotherapy."
]
},
{
"type":"p",
"hlId":"1a8d84",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF"
]
},
" mutation status (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is of paramount importance in patients with melanoma, 40% of whom will have ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF"
]
},
"-mutated tumors. These tumors are highly likely to respond to tyrosine kinase inhibitors targeting ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF"
]
},
", but such mutations are exceedingly rare in upper gastrointestinal malignancies, and routine testing is not indicated."
]
},
{
"type":"p",
"hlId":"8c89e9",
"children":[
"Epidermal growth factor receptor (",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"EGFR"
]
},
") mutation status (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is relevant to the use of anti-",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"EGFR"
]
},
" tyrosine kinase inhibitors in nonâ€“small cell lung cancer; however, these agents have not been demonstrated to be active in gastrointestinal cancers and so are not part of the treatment paradigm."
]
},
{
"type":"p",
"hlId":"60f130",
"children":[
"A PET/CT (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") will not add useful information because the available CT scan demonstrates unequivocal metastatic disease, and any further information from the PET scan would not change the treatment approach, which will be systemic chemotherapy. Any further information regarding extent of disease that might be found on PET/CT would not be expected to change management."
]
}
],
"relatedSection":"mk19_a_on_s5_4",
"objective":{
"__html":"Evaluate metastatic gastroesophageal cancer."
},
"references":[
[
"Greally M, Agarwal R, Ilson DH. Optimal management of gastroesophageal junction cancer. Cancer. 2019;125:1990-2001. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30973648",
"target":"_blank"
},
"children":[
"PMID: 30973648"
]
},
" doi:10.1002/cncr.32066"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":13,
"B":21,
"C":37,
"D":29,
"E":0
},
"hlIds":[
"5784b0",
"cd8db4",
"28f22d",
"983777",
"2663fc",
"bfd989",
"a208b8",
"1a8d84",
"8c89e9",
"60f130"
]
}